---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-025392"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2023-02-24T23:59:59+00:00"
generated_at: "2026-06-19T00:53:08.546155+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics prices $5.5M public offering of 1.05M shares at $5.25/share

## Summary
- Gross proceeds ~$5.5M from 1,050,000 shares at $5.25/share; net proceeds ~$4.8M after discounts and expenses.
- Underwriters granted 30-day option to purchase up to 157,500 additional shares.
- Proceeds to fund clinical asset ATRN-119, pre-clinical ATRN-W1051, and general corporate purposes.
- Offering expected to close Feb 27, 2023; Maxim Group LLC sole book-runner.

## SEC filing metadata
- accession: 0001104659-23-025392
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2023-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465923025392/0001104659-23-025392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465923025392/tm237532d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-025392
- JSON: https://secwatch.observer/filing/0001104659-23-025392.json
- Plain text: https://secwatch.observer/filing/0001104659-23-025392.txt

## Key facts
- Material Agreements
  Aprea Therapeutics, Inc. entered into Underwriting Agreement with Maxim Group LLC valued at approximately $4.8 million (effective 2023-02-22).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Maxim Group LLC
  - Value: approximately $4.8 million
  - Effective: 2023-02-22
  source text: On February 22, 2023, Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC as representative of the underwriters named therein (the “Underwriters”) relating to the issuance and sale of 1,050,000 shares of the Company’s common stock, par value $0.001 per share (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465923025392/0001104659-23-025392-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.